[Correspondence] Multicancer detection tests: holy grail or cautionary tale?
Data ReadoutnegativeGalleriNegative
AI Analysis
Summary
Grail's Galleri trial involving 140,000 UK residents failed to meet its primary endpoint of reducing late-stage cancer detection in a randomized controlled study presented at ASCO 2026. The negative result represents a significant setback for the multicancer detection blood test field.
Clinical Trial Data
Primary Endpoint
Not Met
Patients
140,000
Outcome Details
Galleri trial failed to meet primary endpoint of reducing late-stage cancers
Importance:8/10
Sentiment:
-0.85
cancer screeningmulticancer detectionclinical trial failureASCO conferenceblood test
Read the original article
Published by The Lancet on September 21, 2026 10:30 PM